CYP1B1 expression promotes the proangiogenic phenotype of endothelium through decreased intracellular oxidative stress and thrombospondin-2 expression

Blood

Volumn 113, Issue 3, 2009, Pages 744-754

  Tang, Yixin ^a   Scheef, Elizabeth A ^a   Wang, Shoujian ^a   Sorenson, Christine M ^b   Marcus, Craig B ^c   Jefcoate, Colin R ^b   Sheibani, Nader ^a,b  

^a Departments of Ophthalmology and Visual Sciences   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CYTOCHROME P450 1B1; OXYGEN; THROMBOSPONDIN 2; CYTOCHROME P 450 CYP1B1; CYTOCHROME P-450 CYP1B1; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; THROMBOSPONDIN; UNSPECIFIC MONOOXYGENASE;

ANGIOGENESIS; ANTIOXIDANT ACTIVITY; ARTICLE; CAPILLARY; CELL MIGRATION; CELL STRESS; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID PEROXIDATION; MORPHOGENESIS; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; OXYGENATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA; RETROLENTAL FIBROPLASIA; ANIMAL; BIOSYNTHESIS; CELL MOTION; DRUG EFFECT; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; MOUSE MUTANT; NICK END LABELING; PATHOLOGY; PHYSIOLOGY; RETINA BLOOD VESSEL; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANIMALS; ANTIOXIDANTS; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CELL MOVEMENT; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LIPID PEROXIDATION; MICE; MICE, MUTANT STRAINS; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; PHENOTYPE; REACTIVE OXYGEN SPECIES; RETINAL VESSELS; RNA, SMALL INTERFERING; THROMBOSPONDINS;

EID: 60249103007     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-145219     Document Type: Article

References (59)

1. Campochiaro PA. Molecular targets for retinal vascular diseases. J Cell Physiol. 2007;210:575-581.
2. Smith LE, Wesolowski E, McLellan A, et al. Oxygen- induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
3. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res. 2007;2007: 43603.
4. Al-Shabrawey M, Bartoli M, El-Remessy AB, et al. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol. 2005;167:599-607.
5. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes. 2001;50:1938-1942.
6. Kanwar M, Chan PS, Kern TS, Kowluru RA. Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Invest Ophthalmol Vis Sci. 2007;48: 3805-3811.
7. Poulos TL. Cytochrome P450: molecular architecture, mechanism, and prospects for rational inhibitor design. Pharm Res. 1988;5:67-75.
8. Coon MJ. Cytochrome P450: nature's most versatile biological catalyst. Annu Rev Pharmacol Toxicol. 2005;45:1-25.
9. Estabrook RW, Mason JI, Baron J, Lambeth D, Waterman M. Drugs, alcohol and sex hormones: a molecular perspective of the receptivity of cytochrome P-450. Ann N Y Acad Sci. 1973;212:27-49.
10. Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation. 2004;109: 178-183.
11. Fleming I. Cytochrome P-450 under pressure: more evidence for a link between 20-hydroxyeicosatetraenoic acid and hypertension. Circulation. 2005;111:5-7.
12. Hillig T, Krustrup P, Fleming I, Osada T, Saltin B, Hellsten Y. Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J Physiol. 2003;546:307-314.
13. Choudhary D, Jansson I, Rezaul K, Han DK, Sarfarazi M, Schenkman JB. Cyp1b1 protein in the mouse eye during development: an immunohistochemical study. Drug Metab Dispos. 2007; 35:987-994.
14. Chambers D, Wilson L, Maden M, Lumsden A. RALDH-independent generation of retinoic acid during vertebrate embryogenesis by CYP1B1. Development. 2007;134:1369-1383.
15. Murray GI, Melvin WT, Greenlee WF, Burke MD. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol. 2001;41:297-316.
16. Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum Mol Genet. 1997;6:641-647.
17. Buters JT, Sakai S, Richter T, et al. Cytochrome P450 CYP1B1 determines susceptibility to 7, 12- dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci U S A. 1999;96:1977-1982.
18. Gould DB, Smith RS, John SW. Anterior segment development relevant to glaucoma. Int J Dev Biol. 2004;48:1015-1029.
19. Libby RT, Smith RS, Savinova OV, et al. Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science. 2003; 299:1578-1581.
20. Alvarado JA, Alvarado RG, Yeh RF, Franse-Carman L, Marcellino GR, Brownstein MJ. A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells. Br J Ophthalmol. 2005;89:1500-1505.
21. Fleming I. Cytochrome p450 and vascular homeostasis. Circ Res. 2001;89:753-762.
22. Zhao W, Parrish AR, Ramos KS. Constitutive and inducible expression of cytochrome P450IA1 and P450IB1 in human vascular endothelial and smooth muscle cells. In Vitro Cell Dev Biol Anim. 1998;34:671-673.
23. Kerzee JK, Ramos KS. Constitutive and inducible expression of Cyp1a1 and Cyp1b1 in vascular smooth muscle cells: role of the Ahr bHLH/PAS transcription factor. Circ Res. 2001;89:573-582.
24. Eskin SG, Turner NA, McIntire LV. Endothelial cell cytochrome P450 1A1 and 1B1: up-regulation by shear stress. Endothelium. 2004;11:1-10.
25. Wu Z, Wang S, Sorenson CM, Sheibani N. Attenuation of retinal vascular development and neovascularization in transgenic mice over-expressing thrombospondin-1 in the lens. Dev Dyn. 2006;235:1908-1920.
26. Dimaio TA, Wang S, Huang Q, Scheef EA, Sorenson CM, Sheibani N. Attenuation of retinal vascular development and neovascularization in PECAM-1-deficient mice. Dev Biol. 2008;315: 72-88.
27. Su X, Sorenson CM, Sheibani N. Isolation and characterization of murine retinal endothelial cells. Mol Vis. 2003;9:171-178.
28. Kondo S, Scheef EA, Sheibani N, Sorenson CM. PECAM-1 isoform-specific regulation of kidney endothelial cell migration and capillary morphogenesis. Am J Physiol Cell Physiol. 2007;292: C2070-2083.
29. Savas U, Carstens CP, Jefcoate CR. Biological oxidations and P450 reactions. Recombinant mouse CYP1B1 expressed in Escherichia coli exhibits selective binding by polycyclic hydrocarbons and metabolism which parallels C3H10T1/2 cell microsomes, but differs from human recombinant CYP1B1. Arch Biochem Biophys. 1997;347: 181-192.
30. Cho YC, Zheng W, Yamamoto M, Liu X, Hanlon PR, Jefcoate CR. Differentiation of pluripotent C3H10T1/2 cells rapidly elevates CYP1B1 through a novel process that overcomes a loss of Ah Receptor. Arch Biochem Biophys. 2005;439: 139-153.
31. Chun Y-J, Kim S, Kim D, Lee S-K, Guengerich FP. A New Selective and Potent Inhibitor of Human Cytochrome P450 1B1 and Its Application to Antimutagenesis. Cancer Res. 2001;61:8164-8170.
32. Lopes N, Gregg D, Vasudevan S, Hassanain H, Goldschmidt-Clermont P, Kovacic H. Thrombospondin 2 regulates cell proliferation induced by Rac1 redox-dependent signaling. Mol Cell Biol. 2003;23:5401-5408.
33. Simon MC, Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol. 2008;9:285-296.
34. Wang Z, Tang X, Li Y, et al. 20-Hydroxyeicosatetraenoic acid inhibits the apoptotic responses in pulmonary artery smooth muscle cells. Eur J Pharmacol. 2008;588:9-17.
35. Schleicher M, Shepherd BR, Suarez Y, et al. Prohibitin- 1 maintains the angiogenic capacity of endothelial cells by regulating mitochondrial function and senescence. J Cell Biol. 2008;180:101-112.
36. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81-128.
37. Kapphahn RJ, Giwa BM, Berg KM, et al. Retinal proteins modified by 4-hydroxynonenal: identification of molecular targets. Exp Eye Res. 2006; 83:165-175.
38. El-Remessy AB, Al-Shabrawey M, Platt DH, et al. Peroxynitrite mediates VEGF's angiogenic signal and function via a nitration-independent mechanism in endothelial cells. FASEB J. 2007;21: 2528-2539.
39. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol. 2000;12:634-640.
40. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol. 2003;22:63-71.
41. Bornstein P, Agah A, Kyriakides TR. The role of thrombospondins 1 and 2 in the regulation of cellmatrix interactions, collagen fibril formation, and the response to injury. Int J Biochem Cell Biol. 2004;36:1115-1125.
42. Kyriakides TR, Zhu YH, Smith LT, et al. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol. 1998;140:419-430.
43. Lawler J, Sunday M, Thibert V, et al. Thrombospondin- 1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest. 1998;101:982-992.
44. Volpert OV, Tolsma SS, Pellerin S, et al. Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun. 1995;217:326-332.
45. Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem. 2000;275:32167-32173.
46. Yang Z, Strickland DK, Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem. 2001;276:8403-8408.
47. Yang Z, Kyriakides TR, Bornstein P. Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Mol Biol Cell. 2000; 11:3353-3364.
48. Colavitti R, Pani G, Bedogni B, et al. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem. 2002;277: 3101-3108.
49. Chiarugi P, Pani G, Giannoni E, et al. Reactive oxygen species as essential mediators of cell adhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion. J Cell Biol. 2003;161:933-944.
50. Ushio-Fukai M, Alexander RW. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem. 2004;264:85-97.
51. Porter NA, Caldwell SE, Mills KA. Mechanisms of free radical oxidation of unsaturated lipids. Lipids. 1995;30:277-290.
52. Ethen CM, Reilly C, Feng X, Olsen TW, Ferrington DA. Age-related macular degeneration and retinal protein modification by 4-hydroxy-2- nonenal. Invest Ophthalmol Vis Sci. 2007;48: 3469-3479.
53. Shen JK, Dong A, Hackett SF, Bell WR, Green WR, Campochiaro PA. Oxidative damage in agerelated macular degeneration. Histol Histopathol. 2007;22:1301-1308.
54. Fleming I. Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc Med. 2008;18:20-25.
55. Webler AC, Popp R, Korff T, et al. Cytochrome P450 2C9-induced angiogenesis is dependent on EphB4. Arterioscler Thromb Vasc Biol. 2008;28: 1123-1129.
56. Michaelis UR, Xia N, Barbosa-Sicard E, Falck JR, Fleming I. Role of cytochrome P450 2C epoxygenases in hypoxia-induced cell migration and angiogenesis in retinal endothelial cells. Invest Ophthalmol Vis Sci. 2008;49:1242-1247.
57. Chen P, Guo M, Wygle D, et al. Inhibitors of cytochrome P450 4A suppress angiogenic responses. Am J Pathol. 2005;166:615-624.
58. McLaughlin LA, Dickmann LJ, Wolf CR, Henderson CJ. Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metab Dispos. 2008;36:1322-1331.
59. Kimura M, Takabuchi S, Tanaka T, et al. n-propyl gallate activates hypoxia-inducible factor 1 by modulating intracellular oxygen-sensing systems. Biochem J. 2008;411:97-105.